Moxalactam treatment of anaerobic infections in cancer patients.
Of 30 patients with predominantly anaerobic localized infections superimposed on chronic tissue damage related to trauma, ischemia, or tumor, 22 (73%) responded satisfactorily to moxalactam therapy. Moxalactam-resistant anaerobic pathogens emerged in two patients and were responsible for treatment f...
Sábháilte in:
| Foilsithe in: | Antimicrob Agents Chemother |
|---|---|
| Príomhchruthaitheoirí: | , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
American Society for Microbiology (ASM)
1982
|
| Ábhair: | |
| Rochtain ar líne: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC183800/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/6217784/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.22.4.604 |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|